Synthorx, Inc.

The Scripps Research Institute

Synthrox, Inc.

Jerod Ptacin

Carolina E Caffaro

Marcos Milla

Floyd E Romesberg

Yorke Zhang

Aaron W Feldman

Vivian T Dien

Hans Aerni

Emil C Fischer

Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).

Cytokine conjugates for the treatment of autoimmune diseases

Disclosed herein are interleukin (IL)-15 conjugates and use in the treatment of one or more indications. Also described herein include pharmaceutical compositions and kits comprising one or more of IL-15 conjugates. In some embodiments, at least one amino acid residue in the IL-15 conjugate is replaced by the structure of Formula (I) described herein.

IL-15 conjugates and uses thereof

Cytokine conjugates for the treatment of proliferative and infectious diseases

Disclosed herein are methods, compositions and kits for the synthesis of proteins which comprises unnatural amino acids that utilize a mutant tRNA.

Incorporation of unnatural nucleotides and methods thereof

Disclosed herein are compositions, kits, and methods comprising interleukin (IL) conjugates (e.g., IL-2 conjugates) useful for the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).

Il-2 conjugates and methods of use to treat autoimmune diseases

Disclosed herein are interleukin (IL) 15 conjugates and use in the treatment of one or more indications. Also described herein include pharmaceutical compositions and kits comprising one or more of IL-15 conjugates.

Growing community of inventors

La Jolla, CA, United States of America

Jerod Ptacin